LogicBio Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

ContextLogic Holdings

16/05/2022 15:11

* LogicBio Therapeutics Inc  LOGC.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 28 cents per share.
    * Revenue rose 510.8% to $2.82 million from a year ago; 
analysts
expected $900.00 thousand. 
    * LogicBio Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 16.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * LogicBio Therapeutics Inc shares had fallen by 36.8% this
quarter and lost 81.4% so far this year.
    * Wall Street's median 12-month price target for LogicBio
Therapeutics Inc is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 02:10 p.m.  ​All
figures in US dollars unless otherwise stated